ArticleIntestinal research2018
Medication non-adherence in inflammatory bowel diseases is associated with disability.
Article in Intestinal research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 60 citations in OpenAlex.
- Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease.Advances in therapy · 2023Trial
- Treatable traits in inflammatory bowel disease: a conceptual framework for personalized care.EClinicalMedicine · 2026Review
- An adapted health system access framework for avoidable inflammatory bowel disease admissions: a scoping review.Crohn's & colitis 360 · 2026Review
- Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States.Therapeutic advances in gastroenterology · 2026Article
- A scoping review of disease-modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice.British journal of clinical pharmacology · 2025Article
- Self-Care in Patients With Inflammatory Bowel Disease: A Descriptive Cross-Sectional Multicenter Study.Crohn's & colitis 360 · 2025Article
- What the Patient Thinks and What the Patient Does: Placebo, Nocebo, and Therapy Adherence in Ulcerative Colitis.Journal of clinical medicine · 2025Review
- Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition.Intestinal research · 2025Review
- Use of Complementary and Alternative Therapies in People with Inflammatory Bowel Disease.International journal of environmental research and public health · 2024Article
- High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease.European journal of clinical pharmacology · 2024Article
- Motivational Interviewing as a Strategy to Improve Adherence in IBD Treatment: An Integrative Review Amidst COVID-19 Disruptions.Healthcare (Basel, Switzerland) · 2024Review
- Obstacles to Medication Adherence for Patients with Inflammatory Bowel Disease: A Qualitative Study in East China.Patient preference and adherence · 2024Article
- An education-based telehealth group improves the management and clinical outcomes of patients with inflammatory bowel disease in China (THEIM study).United European gastroenterology journal · 2023Article
- Factors contributing to flares of ulcerative colitis in North India- a case-control study.BMC gastroenterology · 2023Article
- Development and Validation of a Remote Monitoring Tool for Assessment of Mild, Moderate, and Severe Infections in Inflammatory Bowel Disease.Journal of Crohn's & colitis · 2023Article
- Beliefs About Medicines and Adherence to Treatment in Turkish Patients with Inflammatory Bowel Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn's Disease Initiated on Biologic or Conventional Agents.Crohn's & colitis 360 · 2022Article
- Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease.Upsala journal of medical sciences · 2022Article
- Medication Adherence and Its Influencing Factors Among Inflammatory Bowel Disease Patients in China.International journal of general medicine · 2022Article
- Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening.Therapeutic advances in gastroenterology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsMedication non-adherence is common in inflammatory bowel diseases (IBD). The short-term consequences of non-adherence include increased disease relapse but the long-term impact upon patients in terms of daily functional impairment are less well characterized. Identifying negative outcomes, such as disability, may encourage adherence.
methodsConsecutive ambulatory IBD subjects completed the Medication Adherence Rating Scale (MARS; non-adherence defined as ≤16), Inflammatory Bowel Diseases Disability Index (IBD-DI; disability: <3.5) and Beliefs about Medicines Questionnaire (high necessity/concerns: ≥16). The primary outcome was the association between medication non-adherence and disability. Secondary outcomes were the predictors of these outcomes.
resultsA total of 173 subjects on IBD maintenance medications were recruited (98 Crohn's disease, 75 ulcerative colitis: median IBD-DI, -5.0; interquartile range [IQR], -14.0 to 4.0 and median MARS, 19.0; IQR, 18 to 20) of whom 24% were non-adherent. Disability correlated significantly with medication non-adherence (r=0.38, P<0.0001). Median IBD-DI for non-adherers was significantly lower than adherers (-16.0 vs. -2.0, P<0.0001). Predictors of disability included female sex (P=0.002), previous hospitalization (P=0.023), management in a referral hospital clinic (P=0.008) and medication concerns (P<0.0001). Non-adherence was independently associated with difficulty managing bowel movements (odds ratio [OR], 3.71; 95% confidence interval [CI], 1.50-9.16, P=0.005), rectal bleeding (OR, 2.69; 95% CI, 1.14-6.36; P=0.024) and arthralgia/arthritis (OR, 2.56; 95% CI, 1.11-5.92; P=0.028).
conclusionsMedication non-adherence was associated with significantly increased disability in IBD. Female gender, higher disease severity and medication concerns were additional predictors of disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.